SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The New Economy and its Winners
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tom Kearney who wrote (9650)11/15/2001 4:43:07 PM
From: Bill Harmond   of 57684
 
Briefing: 15:37 ET Celera Genomics (CRA) 28.09 +2.04 (+7.8%): Stock trading up 8% on midday note from Banc of America: Axys merger a major positive for CRA (should close tomorrow), makes CRA look more like an integrated biopharma. Merger very complementary: Axys has several advanced preclinical project, CRA has money, exposure, and instrumentation. Most promising N-T drug in Axys pipeline is osteoporosis drug that is partnered with MRK (royalty rate high single digits). CRA holding analyst day on Dec 12.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News